Annual Report 2005 - Boehringer Ingelheim

106
3.7 Accounts payable
Residual term Residual term Residual term
Residual term
(in millions of EUR) less than 1 year 1–5 years over 5 years 31.12.2005 31.12.2004 less than 1 year
Bank loans 216 221 43 480 441 190
Other accounts payable 1,549 – 145 1,694 1,445 1,271
of which:
– Trade accounts payable 775 – – 775 516 516
– Advance payments 45 – – 45 66 66
– Notes payable 14 – – 14 17 17
– Accounts payable to
affiliated companies 8 – – 8 7 7
– Accounts payable to
related companies 1 – – 1 6 6
– Other liabilities (*) 706 – 145 851 833 659
(*) of which:
1,765 221 188 2,174 1,886 1,461
– taxes 24 35
– social security contributions 22 17
There were no liabilities secured by mortgages or similar rights on the balance sheet date consistent
with the previous year.
Liabilities due to shareholders amounted to EUR 215 million (2004: EUR 190 million) at year-end.
These were disclosed under “other liabilities”. They stem from the shareholders’ personal taxes arising
from consolidated business activities.
Payments received from the ABS partners in conjunction with the ABS transaction are shown as
short-term loans under “other liabilities” until the underlying accounts receivable are paid off.
Boehringer Ingelheim a n n u a l r e p o r t 2 0 0 5